Background

Interventions for Health Impact

- Between 2020 and 2021, the Uganda National Malaria Control Division (NMCD), Ministry of Health (MOH) conducted a mass distribution campaign in which standard nets (Permanent 2.0, SafeNet, Interceptor, Yorkool), PBO (Permanent 3.0) and Dual Active Ingredient (Royal Guard) were given out.
- Mass distribution campaigns are conducted after every three years based on the assumption that they nets last up to three years. This is the hypothesis that this study set out to test.

Study objectives

Primary objective

To assess the physical durability of LLINs, estimate median survival & identify major determinants of field performance

Secondary objectives

- □ To describe major behavioural aspects of net care and repair and their impact on physical durability
- To assess the insecticidal effectiveness (residue and bio-assay) after three years of field use

Study Design

-0)	24
Distribution	Assess Attrition	
	Integrity Subsample: (30 per site) Bio-assay Subsample: (30 per site) Chemical residue	Follow-up cohort of nets for p integrity and withdraw net sin both Bioassay and HPLC (Cher residue) Lab tests and Analysi months, 24 months and 36 m

1) So far we have completed the baseline and 12 months surveys Data collection and analysis.

- 2) The 12 Months Bioassay and chemical residue (HPLC) tests are ongoing. So far 4 brands are complete for Bioassay and two brands are complete for chemical residue (HPLC)
- 3) The Data collection for 24 Months survey is ongoing (August December 2022)

Durability monitoring of Long lasting insecticidal nets in Uganda, distributed during 2020 mass campaign





- insecticide residue was extracted and quantified against the target dose based on the denier of the net brands. This was done in accordance to the CIPAC and WHO guidelines

hysical mples for mical

onths

Acknowledgements

• We acknowledge the Global fund, Ugandan MoH, participating districts and study participants



Baseline	12 Months
95%	91%
73%	64%
0.77	0.7
0.23	0.3

Nets Attained Optimal effectiveness (Either KD or Mortality)					
Baseline		12 Months			
24	80.0%	4	13.30%		
20	66.7%	3	10%		
30	100.0%	Ongoing	Ongoing		
30	100.0%	24	80%		
28	93.3%	Ongoing	Ongoing		
30	100.0%	30	100.00%		
30	100.0%	7	23.30%		